AVANIR Pharmaceuticals to Webcast Annual Meeting of Shareholders

SAN DIEGO, Mar 12, 2002 /PRNewswire-FirstCall via COMTEX/ -- AVANIR Pharmaceuticals (Amex: AVN) will hold its Annual Meeting of Shareholders on Thursday, March 14, 2002 at 10:00 a.m. Pacific/1:00 p.m. Eastern at AVANIR's corporate headquarters, located at 11388 Sorrento Valley Road, in San Diego, California. The Annual Meeting will be simultaneously webcast and can be accessed via the Internet by going to AVANIR's website at www.avanir.com . For those who cannot listen to the live webcast, an online replay will be available for 60 days at www.avanir.com .

AVANIR Pharmaceuticals, based in San Diego, is a diversified biopharmaceutical company with an FDA-approved drug currently on the market. AVANIR is engaged in research, development, commercialization, licensing and sales of innovative drug products and antibody generation services.

AVANIR press releases, including any forward-looking statements contained therein, should be reviewed in conjunction with the company's Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." Research findings are not always supportable by evidence obtained from subsequent clinical trials. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

For further information, please contact General Information, Kristen McNally, +1-310-407-6548, kmcnally@webershandwick.com, or Analyst/Investors, Tricia Ross, +1-310-407-6540, tross@webershandwick.com, or Media, Al Orendorff, +1-312-640-6775, aorendorff@webershandwick.com, all of FRB Weber Shandwick, for AVANIR Pharmaceuticals; or Investor Relations, Patrice Saxon of AVANIR Pharmaceuticals, +1-858-622-5202, psaxon@avanir.com.

SOURCE AVANIR Pharmaceuticals

CONTACT:
General Information, Kristen McNally,
+1-310-407-6548, kmcnally@webershandwick.com,
or Analyst/Investors, Tricia Ross,
+1-310-407-6540, tross@webershandwick.com,
or Media, Al Orendorff,
+1-312-640-6775, aorendorff@webershandwick.com,
all of FRB Weber Shandwick,
for AVANIR Pharmaceuticals;

or Investor Relations, Patrice Saxon of AVANIR Pharmaceuticals,
+1-858-622-5202, psaxon@avanir.com

URL: http://www.avanir.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.